BMAC Enhanced Coronary Artery Bypass Grafting (CABG)

This study is currently recruiting participants.
Verified March 2012 by Harvest Technologies
Sponsor:
Information provided by (Responsible Party):
Harvest Technologies
ClinicalTrials.gov Identifier:
NCT01061580
First received: December 16, 2009
Last updated: March 16, 2012
Last verified: March 2012
  Purpose

Injection of concentrated bone marrow cells into the myocardium during CABG procedure.


Condition Intervention Phase
Congestive Heart Failure
Device: Harvest SmartPReP2 BMAC System
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dose Response Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting (CABG) Surgery

Resource links provided by NLM:


Further study details as provided by Harvest Technologies:

Primary Outcome Measures:
  • Changes in left ventricular function [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • QOL (Rand 36; Minnesota Living with Heart Failure Questionnaire) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • NYHA or CCS classification evaluation [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Changes in left ventricular ejection fraction [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Changes in left ventricular end-diastolic volume [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Safety [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 20
Study Start Date: May 2010
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CABG plus BMAC Injection
Injection of Bone Marrow Aspirate Concentrate (BMAC) into ischemic myocardium following CABG during the same open procedure
Device: Harvest SmartPReP2 BMAC System
Injection of 10, 15, or 20 cc of BMAC

Detailed Description:

Injection of autologous concentrated bone marrow cells into the myocardium during CABG procedure.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be enrolled in the trial:

  • Age 18 years and ability to understand the planned treatment.
  • Patients with ischemic congestive heart failure requiring by pass surgery
  • Congestive heart failure with ejection fraction 40%.
  • Serum bilirubin, SGOT and SGPT 2.5 time the upper level of normal.
  • Serum creatinine < 3.0 or no dialysis.
  • NYHA performance status > 3.
  • Negative pregnancy test (in women with childbearing potential).
  • Subject has read and signed the IRB approved Informed Consent form
  • Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Creatinine ≤ 3.0 mg / Dl, and/or no dialysis, INR ≤ 1.6 unless on Coumadin, or PTT <1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR<1.6 at the time of randomization/surgery

Exclusion Criteria:

Subjects will be excluded if they meet any of the exclusion criteria:

  • Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study.
  • History of Prior Radiation Exposure for oncological treatment.
  • History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation.
  • History of abnormal Bleeding or Clotting.
  • History of Liver Cirrhosis.
  • Acute Myocardial Infarction < 4 weeks from treatment date.
  • Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemocult unless follow-up studies reveal patient to be cancer free.
  • Active clinical infection being treated by antibiotics within one week of enrollment
  • Terminal renal failure with existing dependence on dialysis
  • Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.
  • Unable to have 250cc bone marrow harvested.
  • Medical risk that precludes anesthesia or ASA Class 5
  • History of ventricular arrhythmia if AICD is not present.
  • History of ventricular aneurysm.
  • Concurrent surgery such as CABG with valve surgery.
  • Minimally Invasive bypass surgery
  • Life expectancy <6 months due to concomitant illnesses
  • Treatment with immunosuppressant drugs (including Prednisone > 5 mg per day)
  • Patients undergoing urgent by pass surgical procedure
  • Patients with HGB A1C > 8.5%
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01061580

Contacts
Contact: Jack Bonasera 508-732-7530 jbonasera@harvesttech.com
Contact: Jeff Lindquist 508-732-7519 jlindquist@harvesttech.com

Locations
India
Medanta The Medicity Recruiting
Gurgaon, Haryana, India, 122 001
Contact: Naresh Trehan, MD     +91- 124 4141414     info@medanta.org    
Principal Investigator: Naresh Trehan, MD            
Sponsors and Collaborators
Harvest Technologies
Investigators
Principal Investigator: Naresh Trehan, MD Medanta-The Medicity
  More Information

No publications provided

Responsible Party: Harvest Technologies
ClinicalTrials.gov Identifier: NCT01061580     History of Changes
Other Study ID Numbers: 2009-1
Study First Received: December 16, 2009
Last Updated: March 16, 2012
Health Authority: India: Drugs Controller General of India

Keywords provided by Harvest Technologies:
Bone Marrow Concentrate
CABG
Cardiac
Stem Cell

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 21, 2013